Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
PIRS

PIRS - Pieris Pharmaceuticals Inc Stock Price, Fair Value and News

$83.97-3.01 (-3.46%)
Market Closed

33/100

PIRS

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

33/100

PIRS

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$80.08

Target 3M

$94.44

Target 6M

$89.36

PIRS Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

PIRS Price Action

Last 7 days

-14.5%

Last 30 days

-19.4%

Last 90 days

16.9%

Trailing 12 Months

583.0%

PIRS RSI Chart

PIRS Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

PIRS Valuation

Market Cap

993.9M

Price/Earnings (Trailing)

-30.19

Price/Sales (Trailing)

21.5

EV/EBITDA

-30.28

Price/Free Cashflow

-39.08

PIRS Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$80.08

Target 3M

$94.44

Target 6M

$89.36

PIRS Fundamentals

PIRS Revenue

Revenue (TTM)

42.9M

PIRS Earnings

Earnings (TTM)

-32.9M

Earnings Growth (Yr)

-67.45%

Earnings Growth (Qtr)

-19.79%

PIRS Profitability

EBT Margin

-76.88%

Return on Equity

-85.1%

Return on Assets

-49.18%

Free Cashflow Yield

-2.56%

PIRS Investor Care

Shares Dilution (1Y)

796.54%

Diluted EPS (TTM)

-2.51

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20240000
202316.7M33.3M47.5M42.9M
202227.0M27.1M28.5M25.9M
202131.7M23.7M24.9M31.4M
202051.0M56.9M44.7M29.3M
201933.5M27.1M33.9M46.3M
201828.1M37.9M42.3M29.1M
20175.9M6.7M9.8M25.3M
20164.0M4.9M5.2M5.8M
20154.2M3.7M4.1M2.9M
201410.7M8.9M7.1M5.4M
20130011.9M12.4M
201200011.4M
Get all data in R, Python etc through our Historical Stock Data APIs

About Pieris Pharmaceuticals Inc

PIRS
Pieris Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in human blood plasma and other bodily fluids. Its lead respiratory Anticalin based drug candidate, elarekibep used for the treatment of asthma; and PRS-220, an oral inhaled Anticalin protein targeting connective tissue growth factor for the treatment of idiopathic pulmonary fibrosis. The company also develops PRS-344/S09501 2that consists of a PD-L1-targeting antibody and 4-1BB-targeting Anticalin proteins. It has a license and collaboration agreement with Les Laboratoires Servier and Institut de Recherches Internationales Servier, AstraZeneca AB, and Seagen Inc.; and license agreements with Technical University of Munich and Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. Pieris Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Boston, Massachusetts.
 CEO
 WEBSITEpieris.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES127

Pieris Pharmaceuticals Inc Frequently Asked Questions

PIRS is the stock ticker symbol of Pieris Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Tue Jan 27 2026, market cap of Pieris Pharmaceuticals Inc is 993.91 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check PIRS's fair value in chart for subscribers.

The fair value guage provides a quick view whether PIRS is over valued or under valued. Whether Pieris Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Pieris Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for PIRS.

As of Tue Jan 27 2026, PIRS's PE ratio (Price to Earnings) is -30.19 and Price to Sales (PS) ratio is 21.5. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. PIRS PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Pieris Pharmaceuticals Inc has provided -0.044 (multiply by 100 for percentage) rate of return.